v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2024   73,225,253      
Beginning balance at Dec. 31, 2024 $ 66,968 $ 0 $ 358,549 $ (291,013) $ (568)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common shares from stock option exercises (in shares)   119,454      
Issuance of common shares from stock option exercises 515   515    
Issuance of common shares from the employee stock purchase plan (in shares)   118,565      
Issuance of common shares from the employee stock purchase plan 1,111   1,111    
Issuance of common shares upon the acquisition of Vidurama, Inc. (in shares)   928,691      
Issuance of common shares upon the acquisition of Vidurama, Inc. 10,041   10,041    
Issuance costs (26)   (26)    
Vesting of restricted stock units (in shares)   2,505,491      
Common stock withheld related to net settlement of equity awards (in shares)   (3,497)      
Common stock withheld related to net settlement of equity awards (43)   (43)    
Stock-based compensation 17,494   17,494    
Foreign currency translation adjustments, net of tax 348       348
Net unrealized gain (loss) on investments 5       5
Net loss (17,536)     (17,536)  
Ending balance (in shares) at Jun. 30, 2025   76,893,957      
Ending balance at Jun. 30, 2025 78,877 $ 0 387,641 (308,549) (215)
Beginning balance (in shares) at Mar. 31, 2025   74,914,866      
Beginning balance at Mar. 31, 2025 68,581 $ 0 368,919 (299,838) (500)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common shares from stock option exercises (in shares)   33,242      
Issuance of common shares from stock option exercises 52   52    
Issuance of common shares upon the acquisition of Vidurama, Inc. (in shares)   928,691      
Issuance of common shares upon the acquisition of Vidurama, Inc. 10,041   10,041    
Issuance costs (26)   (26)    
Vesting of restricted stock units (in shares)   1,018,884      
Common stock withheld related to net settlement of equity awards (in shares)   (1,726)      
Common stock withheld related to net settlement of equity awards (17)   (17)    
Stock-based compensation 8,672   8,672    
Foreign currency translation adjustments, net of tax 294       294
Net unrealized gain (loss) on investments (9)       (9)
Net loss (8,711)     (8,711)  
Ending balance (in shares) at Jun. 30, 2025   76,893,957      
Ending balance at Jun. 30, 2025 $ 78,877 $ 0 387,641 (308,549) (215)
Beginning balance (in shares) at Dec. 31, 2025 78,353,381 78,353,381      
Beginning balance at Dec. 31, 2025 $ 82,384 $ 0 401,576 (319,065) (127)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common shares from stock option exercises (in shares) 379,012 379,012      
Issuance of common shares from stock option exercises $ 427   427    
Issuance of common shares from the employee stock purchase plan (in shares)   238,230      
Issuance of common shares from the employee stock purchase plan 1,044   1,044    
Vesting of restricted stock units (in shares)   1,500,789      
Common stock withheld related to net settlement of equity awards (in shares)   (558,009)      
Common stock withheld related to net settlement of equity awards (2,874)   (2,874)    
Stock-based compensation 14,410   14,410    
Foreign currency translation adjustments, net of tax (360)       (360)
Net unrealized gain (loss) on investments (35)       (35)
Net loss $ (10,027)     (10,027)  
Ending balance (in shares) at Jun. 30, 2026 79,913,403 79,913,403      
Ending balance at Jun. 30, 2026 $ 84,969 $ 0 414,583 (329,092) (522)
Beginning balance (in shares) at Mar. 31, 2026   79,384,905      
Beginning balance at Mar. 31, 2026 83,277 $ 0 408,518 (324,835) (406)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common shares from stock option exercises (in shares)   29,651      
Issuance of common shares from stock option exercises 102   102    
Vesting of restricted stock units (in shares)   739,356      
Common stock withheld related to net settlement of equity awards (in shares)   (240,509)      
Common stock withheld related to net settlement of equity awards (1,290)   (1,290)    
Stock-based compensation 7,253   7,253    
Foreign currency translation adjustments, net of tax (105)       (105)
Net unrealized gain (loss) on investments (11)       (11)
Net loss $ (4,257)     (4,257)  
Ending balance (in shares) at Jun. 30, 2026 79,913,403 79,913,403      
Ending balance at Jun. 30, 2026 $ 84,969 $ 0 $ 414,583 $ (329,092) $ (522)